The US Food and Drug Administration (FDA) has cleared Revvity’s automated chemiluminescence-based ... family of ChLIA automation solutions with assays that serve diverse patient populations ...

Comprehensive Assay Portfolio: Beyond traditional chemiluminescence applications, it supports advanced diagnostics for specialized conditions such as stroke, Alzheimer's disease, thrombosis, and ...

Comprehensive Assay Portfolio: Beyond traditional chemiluminescence applications, it supports advanced diagnostics for specialized conditions such as stroke, Alzheimer's disease, thrombosis ...